News articles about Lipocine (NASDAQ:LPCN) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lipocine earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.8844430715152 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Lipocine (NASDAQ:LPCN) traded down $0.04 on Wednesday, reaching $1.32. 160,365 shares of the company were exchanged, compared to its average volume of 870,200. Lipocine has a one year low of $1.26 and a one year high of $5.33. The company has a market cap of $27.98, a price-to-earnings ratio of -1.38 and a beta of 0.11.
Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. analysts expect that Lipocine will post -1.04 EPS for the current fiscal year.
A number of research firms recently commented on LPCN. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $11.00 price target on shares of Lipocine in a research note on Thursday, January 11th. Canaccord Genuity lowered shares of Lipocine from a “buy” rating to a “hold” rating in a report on Thursday, January 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Lipocine in a report on Friday, December 8th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $13.50.
TRADEMARK VIOLATION WARNING: “Lipocine (LPCN) Earning Somewhat Positive News Coverage, Analysis Shows” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/31/lipocine-lpcn-getting-somewhat-positive-press-coverage-study-shows.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.